QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Omada Health (OMDA)

Healthcare

No action
Fundamental
3
Sentiment
3
Technical
2

Do Nothing: technicalScore 2/5 — OMDA is a broken daily downtrend (price 14.33 below SMA20 17.76, SMA50 19.30 and SMA200 17.71 with MACD -1.36 and expanding), so no bullish entry clears the score floor; no pullback/oversold limit qualifies (trend-alignment gate: price < SMA50 with MACD < 0 = countertrend), and no breakout stop qualifies (a push through the settled 2026-11-13 high 14.88 would be a countertrend bounce, not a confirmed momentum breakout).

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

Omada Health, Inc. provides virtual care programs in the U.S., focusing on cardiometabolic conditions, physical therapy, weight management, and behavioral health. The company serves employers, health plans, and pharmacy benefits managers, operating through direct sales and channel partners.

Fundamental

fair
Fundamental3
Mixed and uncertain

Omada Health shows strong revenue growth and profitability but faces high customer concentration and internal control issues.

Omada Health pairs 35-40% revenue growth and expanding gross margins with its first GAAP profit and positive free cash flow, funded by a zero-debt balance sheet holding $243.2M of cash. Against that sit extreme Cigna concentration (about two thirds of revenue), an unremediated internal-control material weakness, roughly 60x trailing earnings after a 44% drawdown, and persistent insider selling with no open-market buys. Verdict: mixed and uncertain — a credible turnaround in profitability that is not yet de-risked.

Sentiment

fair
Sentiment3
Mixed / forming

Positive media sentiment contrasts with insider selling and no immediate catalysts.

Dominant catalyst is the 2026-11-05 Q3 2026 print — revenue $91M (+34%), EPS $0.17 vs $0.09 consensus and a raised FY2026 outlook, confidence 'announced' and only partially priced — and scored media sentiment improved from a mildly negative baseline (polarity_score ≈ -0.10, insider-sale dominated) to a clearly positive scoring window (≈ +0.44), a determinate positive delta, yet the equity's own tape has de-rated roughly 40% from September Form 4 prices ($22.77-$25.06) to $14.33 with a fresh in-window CEO Form 4 sale. With no forward-dated catalyst inside 30 trading days the trailing-catalyst ceiling holds the setup in the mixed tier, and a moderate red-flag cap for conflicting catalyst signals applies (bullish print vs. bearish insider sale and tape).

Technical

weak
Technical2
Broken downtrend

The stock is in a confirmed downtrend with no bullish entry signals.

OMDA's daily chart is a broken downtrend, not an emerging bullish setup. Price 14.33 sits below every trend measure on the board — SMA20 17.76 (-19.3%), SMA50 19.30 (-25.8%), SMA200 17.71 (-19.1%), EMA9 15.90, EMA21 17.34, WMA9 15.42, WMA21 17.00, DEMA14 15.04 and the 2026-11-13 daily VWAP 14.555 — and is 43.7% below the 2026-08 high of 25.45, having broken down from an 18-20 area in early November (2026-11-06 -5.69% on 4.7M shares, then five lower closes into 14.33). Momentum confirms the direction: MACD line -1.36 vs signal -0.98 with histogram -0.39 and widening, and ADX14 28.63 (rising from 18.9 on 2026-11-02) with price beneath all averages is a strong DOWN trend, not a bullish one. The only constructive argument is mean reversion: RSI14 29.55 and Williams %R -97.55 are deeply oversold and the last bar closed near its regular-session low (14.185), so a reflex bounce is possible — that is precisely the 'bounce-only, weak bearish' profile that scores 2, not 3. A pullback/oversold limit is additionally barred by the trend-alignment gate (price 14.33 < sma50 19.30 AND macdLine -1.36 < 0 = countertrend bid). A buy stop above the settled 2026-11-13 high 14.88 is mechanically plannable (swingLow 14.185 in-window, buffer 0.22, stop 13.97, risk 0.93 = 0.85xATR vs the 0.5xATR floor, R/R 2.20/0.93 = 2.37) but the chart shows no genuine momentum breakout — a push through 14.88 inside a falling stack with expanding negative MACD would be a countertrend bounce high, so technicalScore 2 < 3 keeps the trade closed. Do Nothing.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.